BioSpace News Archive

The Biosimilars Market size is expected to reach USD 88.12 Billion in 2030 and register a revenue CAGR of 21.3% over the forecast period, according to the latest report by Reports and Data.

The global cervical cancer diagnostics market size is expected to reach USD 9,180.63 Million in 2030 and register a revenue CAGR of 5.0% over the forecast period, according to latest report by Reports and Data.

The Glucose Meter Market size is expected to reach USD 21.27 Billion in 2030 and register a revenue CAGR of 9.5% over the forecast period, according to latest report by Reports and Data

The global genomics market size is expected to reach USD 129.34 Billion in 2030 and register a revenue CAGR of 19.0% over the forecast period, according to the latest report by Reports and Data.

The global medical foods market size is expected to reach USD 33.85 Billion in 2030 and register a revenue CAGR of 5.4% over the forecast period, according to latest report by Reports and Data.

The Center for Breakthrough Medicines (CBM) in partnership with the Discovery Labs announced today the acceleration of plans to build capacity to manufacture more than 10,000 patient therapies in direct response to the critical shortage of cell therapy supply, which will help patients win their courageous battles against cancer.

The global ultrasound gel market size is expected to reach USD 126.2 Million in 2030 and register a revenue CAGR of 3.4% over the forecast period, according to a latest report by Reports and Data.

Fauna Bio, a biotechnology company pioneering the fields of comparative, computational and translational genomics, is celebrating its fourth birthday this month with the release of Centaur, a knowledge graph that is the first of its kind to visualize the intersection between animal gene expression data and human diseases in one comprehensive map.

OncoPep, Inc. is proud to be a participant at this year’s BIO International Convention 2022 conference June 13-16 in San Diego CA.

Covis Pharma GmbH, an affiliate of Group S.à r.l., announced that the U.S. Food & Drug Administration anticipates holding a meeting of the Obstetrics, Reproductive and Urologic Drugs Advisory Committee on October 17-19, 2022, to conduct a hearing about the future of Makena®.